Featured News
Press Release
Alzheimer’s Association Statement on European Medicines Agency Negative Opinion on Leqembi for the Treatment of Alzheimer’s Disease
CHICAGO, July 26, 2024 — The Alzheimer’s Association is disappointed by today’s decision by the European Medicines Agency (EMA) to recommend against allowing Leqembi® to be marketed across the Eu...
All News
Press Release
House Introduces Bipartisan Legislation to Renew BOLD Commitment to Dementia Public Health Infrastructure
Washington, D.C., February 5, 2024 — Today, the House began renewing our nation’s commitment to strengthening the dementia public health...
AIM Blog
Recognizing AIM’s February Advocate of the Month: Pamela Talley
Each month, we’re featuring an advocate who engages with policymakers to ensure priorities that improve the lives of people impacted...
Press Release
Biogen’s Decision to Discontinue Alzheimer’s Drug
CHICAGO, Jan. 31, 2024 — Despite today’s announcement from Biogen, the Alzheimer’s Association is extremely optimistic about the future of...
AIM Blog
To Improve the Early Detection and Diagnosis of Alzheimer’s, States Need to Ensure Access to Biomarker Testing
With the historic Food and Drug Administration (FDA) approval of treatments that slow the progression of Alzheimer’s in the early...
AIM Blog
Recognizing AIM’s January Advocate of the Month: Mary Dysart Hartt
Each month, we’re featuring an advocate who engages with policymakers to ensure priorities that improve the lives of people impacted...
AIM Blog
State Spotlight: South Carolina
Thanks to our dedicated advocates in all 50 states, AIM is leading the way to advance legislation to improve the...